Human malignant pleural mesothelioma (hMPM) is a highly aggressive cancer for which immunotherapy with nivolumab + ipilimumab (anti PD-1 + anti CTLA-4, respectively) is the standard-of-care. This evidence concerns the gene CTLA4 and malignant pleural mesothelioma.